PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage regenerative medicine company focused on the treatment of chronic kidney disease, which completed its transition from blank-check company to publicly traded operating entity through the SPAC process. The company's IPO prospectus, filed on Form 424B4 in July 2021, marked the vehicle's entry to public markets in the healthcare and biotechnology sector. ProKidney's lead investigational program, REACT (Renal Autologous Cell Therapy), targets progressive chronic kidney disease using cell-based therapy derived from patients' own kidney cells. The company subsequently completed its de-SPAC business combination, bringing the kidney-focused platform into the public arena. Investors seeking complete filing history, shareholder data, and transaction timelines for PROK can access the full dataset by signing up at SpacDesk.